1. Home
  2. MREO vs FFIC Comparison

MREO vs FFIC Comparison

Compare MREO & FFIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • FFIC
  • Stock Information
  • Founded
  • MREO 2015
  • FFIC 1929
  • Country
  • MREO United Kingdom
  • FFIC United States
  • Employees
  • MREO N/A
  • FFIC N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • FFIC Major Banks
  • Sector
  • MREO Health Care
  • FFIC Finance
  • Exchange
  • MREO Nasdaq
  • FFIC Nasdaq
  • Market Cap
  • MREO 424.5M
  • FFIC 427.6M
  • IPO Year
  • MREO N/A
  • FFIC 1995
  • Fundamental
  • Price
  • MREO $2.15
  • FFIC $12.03
  • Analyst Decision
  • MREO Strong Buy
  • FFIC Hold
  • Analyst Count
  • MREO 7
  • FFIC 3
  • Target Price
  • MREO $7.71
  • FFIC $16.17
  • AVG Volume (30 Days)
  • MREO 943.2K
  • FFIC 183.4K
  • Earning Date
  • MREO 05-13-2025
  • FFIC 07-28-2025
  • Dividend Yield
  • MREO N/A
  • FFIC 7.28%
  • EPS Growth
  • MREO N/A
  • FFIC N/A
  • EPS
  • MREO N/A
  • FFIC N/A
  • Revenue
  • MREO N/A
  • FFIC $124,028,000.00
  • Revenue This Year
  • MREO N/A
  • FFIC $111.92
  • Revenue Next Year
  • MREO $54.91
  • FFIC $7.50
  • P/E Ratio
  • MREO N/A
  • FFIC N/A
  • Revenue Growth
  • MREO N/A
  • FFIC N/A
  • 52 Week Low
  • MREO $1.58
  • FFIC $10.65
  • 52 Week High
  • MREO $5.02
  • FFIC $18.59
  • Technical
  • Relative Strength Index (RSI)
  • MREO 40.94
  • FFIC 42.40
  • Support Level
  • MREO $2.12
  • FFIC $11.95
  • Resistance Level
  • MREO $2.27
  • FFIC $12.36
  • Average True Range (ATR)
  • MREO 0.13
  • FFIC 0.27
  • MACD
  • MREO -0.02
  • FFIC -0.09
  • Stochastic Oscillator
  • MREO 9.09
  • FFIC 11.41

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About FFIC Flushing Financial Corporation

Flushing Financial Corp operates as a bank holding company, which is engaged in the provision of banking and financial services. It provides Personal, Business, lending, Government banking, and Card services. Its principal business is attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, in originations and purchases of multi-family residential properties, commercial business loans, commercial real estate mortgage loans, construction loans, small business administration loans, and other small business loans.

Share on Social Networks: